Effects of astemizole on ventricular activation, effective refractory periods, RT intervals, and programmed stimulation-induced ventricular arrhythmias in dog hearts with myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 2, 1998, Pages 286-291

  Hashimoto, Hisakuni ^a   Nishimoto, Masahiko ^a   Ohmura, Tomohiro ^a   Watanabe, Shinji ^a   Ikeda, Yasuhiko ^a   Nakamura, Ryuta ^a   Umemura, Kazuo ^a   Nakashima, Mitsuyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arrhythmias; Astemizole; Effective refractory period; Ischemic heart; Ventricular activation

Indexed keywords

ASTEMIZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; ELECTROSTIMULATION; HEART ATRIUM PACING; HEART INFARCTION; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONTRACTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARRHYTHMIA; ASTEMIZOLE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEMODYNAMIC PROCESSES; HISTAMINE H1 ANTAGONISTS; MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION;

EID: 0031935453     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199802000-00015     Document Type: Article

References (29)

1. Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988;42:257-9.
2. Nightingale SL. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992;268:705.
3. Honig PK, Woosley RL, Zamani K, Coner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
4. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
5. Sakemi H, VanNatte B. Torsades de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 1993;125:1436-8.
6. Koh KK, Rim MS, Yoon J, Kim SS. Torsades de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994;7:343-6.
7. 1 antagonists: comparative studies with loratidine, terfenadine and sedating antihistamines in guinea-pigs. Clin Exp Allergy 1995;25:974-84.
8. Hey JA, Del Prado M, Sherwood J, Kreutner W, Egan RW. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996;46:153-9.
9. + channel cloned from human heart. Mol Pharmacol 1993;44:1240-5.
10. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:15432-6.
11. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995;76:110-9.
12. Harris AA. Delayed development of ventricular ectopic rhythm following experimental coronary occlusion. Circulation 1950;1:1318-28.
13. Woestenborgs RL, Geuens I, Michiels M, Heykants J. Radioimmunoassay procedures for astemizole and metabolites in plasma. Drug Dev Res 1986;8:63-9.
14. Lang DG, Wang CM, Wenger TL. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. J Cardiovasc Pharmacol 1993;22:438-42.
15. + channels in guinea-pig ventricular myocytes. J Cardiovasc Pharmacol 1995;26:761-9.
16. Tanaka H, Masumiya H, Kato Y, Shigenobu K. Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardium. Gen Pharmacol 1996;27:337-40.
17. El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Reentrant ventricular arrhythmias in the late myocardial infarction period. 4. Mechanism of action of lidocaine. Circulation 1977;56:395-402.
18. Hashimoto H, Satoh N, Nakashima M. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride, a new class I antiarrhythmic drugs, on ventricular arrhythmias, intraventricular conduction and the refractory period in canine myocardial infarction. J Cardiovasc Pharmacol 1992;19:417-24.
19. El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Reentrant ventricular arrhythmias in the late myocardial infarction period: conduction characteristics in the infarction zone. Circulation 1977; 55:686-702.
20. Bigger JT, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Rall TW, Nies AS, Taylar P. eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Macmillan, 1990:840-73.
21. Vildmair V, Podrid P, Lown B, Cohn B, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886-94.
22. The working group on arrhythmias of the European Society of Cardiology. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991;12:1112-31.
23. Kidwell GA, Gonzalez MD. Effects of flecainide and d-sotalol on myocardial conduction and refractoriness; relation to antiarrhythmic and proarrhythmic drug effects. J Cardiovasc Pharmacol 1993;21:621-32.
24. Sanchez PJ, Zaldivar HM. The effects of benzodiazepine drugs and antihistamines in experimental postinfarction arrhythmias. Arch Inst Cardiol Mex 1993;63:185-9.
25. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995;91:2220-5.
26. Oonishi A, Oosawa N, Nakai Y, Naha H. Pharmacokinetics of astemizole in healthy volunteers. J Clin Ther Med 1991;7:1437-65.
27. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantillena LR. Terfenadine-ketoconazole interaction: pharmacokinetics and electrocardiographic consequences. JAMA 1993;269: 1513-8.
28. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetics interaction. J Clin Pharmacol 1994;34:1222-7.
29. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatic cellular carcinoma. Intern Med 1995;34:92-5.